1. Pfizer has accused Johnson & Johnson of using exclusionary contracts that prevent payers from utilizing Inflectra, Pfizer’s biosimilar version of J&J’s Remicade. (Bloomberg)
2. President Trump again took to Twitter to criticize pharmaceutical pricing practices. On Monday, after Merck CEO Ken Frazier resigned from Trump’s manufacturing council in the wake of the president’s initial response to the Charlottesville protests, Trump criticized Frazier for raising drug prices. (The Hill)
3. WebMD plans to reposition itself as a platform where consumers “can take action” and better manage their health. The company announced last month that it would be acquired by private-equity firm KKR. (WSJ)
4. The FDA disclosed new rules that will make it harder for the agency to hire foreign scientists, who now must have lived in the U.S. for at least three of the last five years. (Stat)
5. The Bitfury Group partnered with Insilico Medicine, an artificial intelligence firm for the healthcare industry, to create new applications using blockchain. (Reuters)
